[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346786-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346786-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","zdhhc9-palmitoylates-lamtor1-to-promote-renal-cell-carcinoma-malignant-progression","ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression","","Renal cell carcinoma (RCC) remains difficult to treat due to invasiveness, metastasis, and resistance to conventional therapies. The lysosomal regulator LAMTOR1 coordinates mTORC1 recruitment to the lysosomal surface, linking mTOR signaling to cancer progression. This study shows that ZDHHC9 activates the mTOR pathway by palmitoylating LAMTOR1 at Cys3/4, enhancing mTORC1 recruitment and downstream signaling. These findings identify ZDHHC9 as a key mediator and potential diagnostic and therapeutic target for RCC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/zdhhc9-palmitoylates-lamtor1-to-promote-renal-cell-carcinoma-malignant-progression/346786/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/zdhhc9-palmitoylates-lamtor1-to-promote-renal-cell-carcinoma-malignant-progression/346786.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does LAMTOR1 play in mTOR signaling?","Question",{"text":63,"@type":64},"LAMTOR1 recruits mechanistic target of rapamycin complex 1 (mTORC1) to the lysosomal surface, thereby influencing cell growth and cancer progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does ZDHHC9 affect renal cell carcinoma progression?",{"text":68,"@type":64},"ZDHHC9 palmitoylates LAMTOR1 at Cys3/4 residues, which enhances mTORC1 recruitment and accelerates activation of the mTOR signaling cascade.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is ZDHHC9 proposed as a potential clinical target for RCC?",{"text":72,"@type":64},"The study positions ZDHHC9 as a key mediator of RCC progression through LAMTOR1 palmitoylation, suggesting value for diagnosis and treatment of this malignancy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346786,1790949417,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression  \nBo Liu1,2,6, Tao Hou3,6, Xizhi Liu1, Lu Liu1,4, Zhiqiang Ma5 ✉ and Yujiao Zhang1 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | The lysosomal regulator complex member LAMTOR1 serves as a crucial pivot that recruits the mechanistic target of rapamycin complex 1 (mTORC1) to the lysosomal surface, thereby inﬂuencing biological processes such as cell growth and cancer progression. In renal cell carcinoma (RCC), existing studies reveal that mTORC1 signaling contributes to cancer progression. However, the precise regulatory mechanisms underlying mTOR signaling in RCC remain unclear and warrant further investigation. Here, we demonstrate that the palmitoylation enzyme Zinc Finger DHHC-Type Containing 9 (ZDHHC9) activates the mTOR signaling pathway, thereby accelerating cancer progression and highlighting its potential role in RCC. In our study, we identiﬁed that ZDHHC9 speciﬁcallypalmitoylates LAMTOR1 at its Cys3/4 residues, enhancing the recruitment of mTORC1 and subsequently activating the mTOR signaling cascade. Collectively, our ﬁndings provide novel insights into the pathogenesis of RCC and establish ZDHHC9 as a key mediator of RCC progression through the palmitoylation of LAMTOR1, which may serve as a promising target for the diagnosis and |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| treatment of this malignancy. |  |  |\n|  | Cell Death and Disease (2026)17:323; [https://doi.org/10.1038/s41419-026-08558-8](https://doi.org/10.1038/s41419-026-08558-8) |  |\n|  |  |  |\n\nINTRODUCTION  \nRenal cell carcinoma (RCC), which originates from the tubular epithelium, accounts for over 80% of renal malignancies and ranks among the top eight most common cancers, with an annual incidence increase of 1.6%[1] . Characterized by high invasiveness, strong metastatic potential, elevated mortality rates, and heterogeneous clinical progression, clear cell renal cell carcinoma (ccRCC) is associated with a poor prognosis [2, 3] . Surgical resection remains the primary treatment for localized tumors; however, approximately 25% of patients are diagnosed with advanced or metastatic disease at presentation [4] . Metastatic transformation is closely associated with poor clinical outcomes, as mRCC demonstrates resistance to conventional radiotherapy and chemotherapy, develops multidrug tolerance, and consequently leads to a less than 5-year survival rate for the majority of patients [5] . These factors highlight the pressing requirement for innovative therapeutic approaches to address this notoriously treatment-resistant malignancy.  \nPalmitoylation of proteins is a post-translational modiﬁcation wherein fatty acyl moieties, typically 16-carbon palmitate, are covalently attached to cysteine residues of substrate proteins via the ZDHHC enzyme family. This process primarily regulates the trafﬁcking and localization of substrate proteins among cell membranes, organelles, and nuclei [6] . Palmitoylation has been demonstrated to play a critical role in promoting liver cancer metastasis by modulating the CKAP4/EGFR signaling pathway and activating immunosuppressive cells, such as myeloid-derived  \nsuppressor cells [7–9] . In addition, approximately 150 cancer studies have identiﬁed palmitoylation enzymes ZDHHCx as potential contributors to the malignant progression of carcinomas [10, 11] . Meanwhile, it has been demonstrated that targeting ZDHHCx using their inhibitors, such as Cerulean or Orlistat, can enhance sensitivity to immune checkpoint therapy [12, 13] . Database analysis showed that the mRNA levels of ZDHHC9 in renal cell carcinoma (RCC) surpass those of other ZDHHCx family members and are signiﬁcantly higher than in normal renal tissues [14] . The data from the cBioPortal database indicate that the ampliﬁcation frequency of ZDHHC9 in ","cbCaiebpy63ZFDxM","https://ap.wps.com/l/cbCaiebpy63ZFDxM","pdf",4689061,12,"English","# Introduction\n## Background on renal cell carcinoma and mTOR signaling\n## Palmitoylation and ZDHHC family in cancer progression\n# Results\n## ZDHHC9 palmitoylates LAMTOR1 at Cys3/4\n## Effects on mTORC1 recruitment and mTOR signaling activation\n# Conclusion\n## ZDHHC9 as a mediator and potential target in RCC","[{\"question\":\"What role does LAMTOR1 play in mTOR signaling?\",\"answer\":\"LAMTOR1 recruits mechanistic target of rapamycin complex 1 (mTORC1) to the lysosomal surface, thereby influencing cell growth and cancer progression.\"},{\"question\":\"How does ZDHHC9 affect renal cell carcinoma progression?\",\"answer\":\"ZDHHC9 palmitoylates LAMTOR1 at Cys3/4 residues, which enhances mTORC1 recruitment and accelerates activation of the mTOR signaling cascade.\"},{\"question\":\"Why is ZDHHC9 proposed as a potential clinical target for RCC?\",\"answer\":\"The study positions ZDHHC9 as a key mediator of RCC progression through LAMTOR1 palmitoylation, suggesting value for diagnosis and treatment of this malignancy.\"}]","ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression | PDF",1790062755,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1b459bf89a3cd9361451f92d298fa9b.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/770ab288876a01a64800e7594f4a101e.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e58961adefaa675990dac41e2bec357d.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc545c72b1dfb6890b8d4533d14aad1c.webp",980,1301]